Navigation Links
USB OptiKinase Eliminates Base Bias in Labeling of Oligonucleotide 5'-Ends

Wild-type T4 Polynucleotide Kinase (PNK)(1,2,3) is commonly used for phosphorylation and labeling of 5'-ends of DNA and oligonucleotides. Labeling, in particular, can be accomplished by two approaches, the forward reaction and the exchange reaction (Fig. 1)(3). Historically, T4 PNK has played a crucial role in molecular biology and it continues to be important in applications such as labeling of probes for hybridization, sequencing or mapping of transcripts and in phosphorylation of DNA ends for cloning(3,4). Although T4 PNK continues to be widely used, the enzyme exhibits two limitations. First, T4 PNK exhibits base bias; the effectiveness of phosphorylation depends on the base at the 5'-end of the oligonucleotide target, with 5'-C exhibiting the lowest extent of phosphorylation(5). Second, T4 PNK can be challenging to use; precise enzyme titrations and careful optimization of reaction times are often required in order to achieve desired results(3,6). USB OptiKinase overcomes these limitations, greatly simplifying and improving phosphorylation and labeling reactions.

OptiKinase is a recombinant version of T4 PNK that has been genetically modified to accomplish uniform and consistent phosphorylation and labeling of 5'-ends of DNA and oligonucleotides. Base bias is dramatically reduced, which should greatly increase uniformity of labeling of diverse templates. The need for careful optimization of reaction conditions is also reduced, which should improve consistency of results between experiments. Finally, lower amounts of radioactive ATP can be used without sacrificing labeling efficiency, resulting in reduced reagent costs. Thus, USB OptiKinase offers substantial advantages over wild-type T4 PNK.

Method

The following protocol corresponds to use of OptiKinase for labeling of oligonucleotides by the forward reaction. T
'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. New Microarray Labeling Kit for Preparing cDNA Probes
2. aRNA Synthesis and Labeling for Array Analysis
3. Amino Allyl Labeling for Array Analysis
4. Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit
5. Efficient Europium Labeling of Lymphokine-Activated Killer Cells Using the Gene Pulser II with RF Module, Rev C
6. Oligonucleotide Purity Analysis by Capillary Electrophoresis
7. Using the OligoGreen Oligonucleotide Quantitation Reagent in the Gemini XS, Gemini EM and SpectraMax M2 Microplate Readers (MaxLine Application Note #21)
Post Your Comments:
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix ... of common shares of Resverlogix have approved the ... Eastern Capital Limited of 5,600,000 units at a ... Placement"), each unit being comprised of one common ... aggregate proceeds of approximately CAD$15 million; and (ii) ...
(Date:6/30/2015)... , June 30, 2015  Today, Americord Registry, one ... announced Andrew Horne , a partner at Kirkland & ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... Americord,s Advisory Board," says Martin Smithmyer , CEO of ... his legal career that will assist Americord,s growth and vision." ...
(Date:6/30/2015)... ... 2015 , ... The maximum number of shares proposed to be purchased in ... of unvested restricted stock). On June 29, 2015, the last trading day prior to ... on the OTCBB was $2.29 per share. , The tender offer will expire on ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... participant in its Phase 1/2 clinical trial of ... unilateral Achilles tendinosis, has been enrolled and their ... ultrasound-guided injections. RCT-01 is comprised of non-bulbar dermal ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) today ... 2007 financial results after the NASDAQ Global Market ... Jack Lief, Arena,s,President and Chief Executive Officer, and ... Financial Officer, will host a conference call,at 5:00 ...
... Phase 3 Trials for Crohn,s Disease, Pouchitis and ... ... Ocera Therapeutics, a,biopharmaceutical company focused on the licensing, development and,commercialization ... liver diseases, has announced the completion of a,$35.5 million Series ...
... Osteotech, Inc.,(Nasdaq: OSTE ), a leader in ... today that total revenue for the year,ending December 31, ... for the year ended December 31, 2006. Revenue from ... for full year,2007, an increase of 15% over core ...
Cached Biology Technology:Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008 2Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008 3Ocera Therapeutics Closes $35.5 Million Series C Financing 2Ocera Therapeutics Closes $35.5 Million Series C Financing 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 2Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 4Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 5Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 6
(Date:6/9/2015)... 2015 Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ... "Gesture Recognition & Touchless Sensing Market by Technology ... Others), Product (Biometric & Sanitary Equipment) & by ... to their offering. The total gesture ... reach $ 23.55 Billion by 2020 at a ...
(Date:6/8/2015)... , June 8, 2015  The Secure ... their selection of Troy Potter of ... immediately. SIBA is a non-profit association that was ... policy, education and implementation of solutions that protect ... ...
(Date:6/4/2015)... the co-chairs of the Blue Ribbon Study Panel on Biodefense ... USA Today,s investigative report ... findings of lax safety standards and called on the federal ... "The state of oversight of ... Lieberman , former senator and co-chair of the Blue Ribbon ...
Breaking Biology News(10 mins):Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5Biodefense Panel Expresses Grave Concerns over Findings at Nation's Research Labs 2Biodefense Panel Expresses Grave Concerns over Findings at Nation's Research Labs 3
... September 8, 2008For allergy sufferers, the choice all too ... curtains or anything that could trigger indoor allergens. ... with the launch of Clorox® Anywhere® Anti-Allergen Fabric Spray, ... fabric surfaces in the home. Clorox® Anywhere® ...
... Francis S. Collins, M.D., Ph.D., a physician-geneticist and ... with the new Inamori Ethics Prize from the Inamori ... Reserve University. Modeled after the Nobel and Kyoto ... Inamori Ethics Prize instead honors outstanding international ethical leaders. ...
... headed by Prof. Daniel Rosenfeld of the Institute of ... come up with a surprising finding to the disputed ... The conclusion: both can be true, depending on local ... is one with significant consequences in an era of ...
Cached Biology News:The Clorox Company's new indoor allergen product reduces common indoor allergens up to 90 percent 2Leader of Human Genome Project honored with the Inamori Ethics Prize 2Dirty air brings rain -- then again, maybe not 2Dirty air brings rain -- then again, maybe not 3
... Acid Resistant SpeedVac Model SPD131DDA , ... The SPD131DDA is designed to handle the rigors ... new slim design, digital display, dual independent timers, ... coated chamber and vapor pathway. , , ...
...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
Biology Products: